Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (630)	5/13/1998 11:34:00 PM
From: Luke	Read Replies (1) \| Respond to of 3202

Hi, Interesting that the ESTs are now allowed. How to put a $ amount to this patent estate seems mind boggling. Have you ever heard of analysts putting numbers to these types of things? It would be really interesting to learn how this is done. It must be expensive to get these patents though - last I heard you had to divide applications into 10 sequences at a time to get them allowed (even though you could file thousands at a time), which I imagine would get real expensive if the future value is not known. Also, i dont think Europe takes any EST patents. So Lehman says $13B/year is from recombinant proteins. I wonder how much of the data from INCYs databases that translates into a protein product discovery actually results in the use of the actual database derived protein as the product (instead of using it to discover something like an associated protein)? So, in order to avoid the patents, one has to make an analog or derivative that does not contain the sequence fragment of the est in the claim? How easy is this in practice? There are cases around where derivatives that have been changed to the point of having more or less activity have not been found to infringe.